Legend Biotech Corp Cash Flow-to-Debt Ratio
Legend Biotech Corp cash flow-to-debt ratio. Legend Biotech Corp (LEGN) has a Cash Flow-to-Debt Ratio of -0.04x as of June 2026, meaning its operating cash flow of $-20.90 Million could theoretically repay 0% of its total liabilities ($521.32 Million) in one year. Check Legend Biotech Corp cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Legend Biotech Corp (2017–2025)
Cash flow-to-debt ratio of Legend Biotech Corp from 2017 to 2025. Historical debt coverage capacity for Legend Biotech Corp across 9 annual periods. Check Legend Biotech Corp cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Legend Biotech Corp Cash Flow-to-Debt Ratio by Year (2017–2025)
Legend Biotech Corp cash flow-to-debt ratio by year from 2017 to 2025. Year-by-year debt coverage analysis for Legend Biotech Corp. For the full cash flow conversion analysis, see Legend Biotech Corp cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.14x | $-100.47 Million | $731.60 Million | ▲ +40.0% |
| 2024 | -0.23x | $-144.03 Million | $629.61 Million | ▲ +65.3% |
| 2023 | -0.66x | $-393.28 Million | $597.24 Million | ▼ -91.9% |
| 2022 | -0.34x | $-201.28 Million | $586.65 Million | ▲ +38.9% |
| 2021 | -0.56x | $-198.47 Million | $353.52 Million | ▲ +69.2% |
| 2020 | -1.82x | $-223.00 Million | $122.27 Million | ▼ -801.5% |
| 2019 | -0.20x | $-83.06 Million | $410.58 Million | ▼ -127.6% |
| 2018 | 0.73x | $307.68 Million | $420.40 Million | ▲ +7077.7% |
| 2017 | -0.01x | $-2.38 Million | $226.53 Million | — |